Dental products company Envista Holdings (NYSE: NVST) will be announcing earnings results tomorrow after market close. Here’s what investors should know.
Envista beat analysts’ revenue expectations by 0.8% last quarter, reporting revenues of $652.9 million, up 1.1% year on year. It was a slower quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates.
Is Envista a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Envista’s revenue to decline 2.3% year on year to $609.1 million, a deceleration from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $0.21 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Envista has missed Wall Street’s revenue estimates four times over the last two years.
Looking at Envista’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Penumbra delivered year-on-year revenue growth of 16.3%, beating analysts’ expectations by 2.7%, and Boston Scientific reported revenues up 20.9%, topping estimates by 2%. Penumbra traded up 7.2% following the results while Boston Scientific was also up 6.5%.
Read our full analysis of Penumbra’s results here and Boston Scientific’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. Envista is down 5.3% during the same time and is heading into earnings with an average analyst price target of $19.83 (compared to the current share price of $16.20).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
